Current clinical trials in amyotrophic lateral sclerosis

被引：28
|
作者：
Bhatt, Jaydeep M. [1 ]
Gordon, Paul H. [1 ]
机构：
[1] Columbia Univ, Dept Neurol, Neurol Inst, Eleanor & Lou Gehrig MDA ALS Res Ctr, New York, NY 10032 USA
来源：
EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2007年 / 16卷 / 08期
基金：
美国国家卫生研究院;
关键词：
amyotrophic lateral sclerosis; clinical trials; excitotoxicity; minocycline; motor neuron degeneration; neuroprotective agents; neurotrophic factors; riluzole;
D O I：
10.1517/13543784.16.8.1197
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Amyotrophic lateral sclerosis is caused by selective degeneration of motor neurons in the brain and spinal cord. There are still no other effective therapies 10 years after the approval of riluzole for the treatment of amyotrophic lateral sclerosis, but advances in drug development and screening are substantially increasing the number of potential therapeutic agents. This review provides an overview of clinical trial methodology in annyotrophic lateral sclerosis followed by a systematic evaluation of drugs that are presently in Phase I, II and III clinical trials. There is an emphasis on the scientific evidence supporting the selection of each drug being tested, as well as on trial design.
引用
收藏
页码：1197 / 1207
页数：11
相关论文
共 50 条
  • [31] Phrenic nerve study as outcome in clinical trials for amyotrophic lateral sclerosis
    Pinto, Susana
    De Carvalho, Mamede
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2021, 22 : 9 - 13
  • [32] How can we improve clinical trials in amyotrophic lateral sclerosis?
    Paul H. Gordon
    Vincent Meininger
    Nature Reviews Neurology, 2011, 7 : 650 - 654
  • [33] Systematic review of the methodological quality of clinical trials in Amyotrophic Lateral Sclerosis
    Pupillo, Elisabetta
    Sassi, Serena
    Arippol, Emilio
    Tinti, Lorenzo
    Vitelli, Eugenio
    Bianchi, Elisa
    Al-Chalabi, Ammar
    Leone, Maurizio
    MUSCLE & NERVE, 2023, 68 : S47 - S47
  • [34] Clinical trials in amyotrophic lateral sclerosis: The tenuous past and the promising future
    Choudry, RB
    Cudkowicz, ME
    JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (12): : 1334 - 1344
  • [35] Innovating Clinical Trials for Amyotrophic Lateral Sclerosis Challenging the Established Order
    van Eijk, Ruben P. A.
    Nikolakopoulos, Stavros
    Roes, Kit C. B.
    Kendall, Lindsay
    Han, Steve S.
    Lavrov, Arseniy
    Epstein, Noam
    Kliest, Tessa
    de Jongh, Adriaan D.
    Westeneng, Henk-Jan
    Al-Chalabi, Ammar
    Van Damme, Philip
    Hardiman, Orla
    Shaw, Pamela J.
    McDermott, Christopher J.
    Eijkemans, Marinus J. C.
    van den Berg, Leonard H.
    NEUROLOGY, 2021, 97 (11) : 528 - 536
  • [36] Retention and Protocol Adherence in Amyotrophic Lateral Sclerosis (ALS) Clinical Trials
    Atassi, Nazem
    Titus, Sarah
    Shapiro, Jordan
    Levine-Weinberg, Mark
    Deng, Jing
    Yu, Hong
    Yerramilli-Rao, Padmaja
    Cudkowicz, Merit
    NEUROLOGY, 2011, 76 (09) : A584 - A584
  • [37] Current concepts on amyotrophic lateral sclerosis
    ArriadaMendicoa, N
    OteroSiliceo, E
    REVISTA ECUATORIANA DE NEUROLOGIA, 1997, 6 (1-2): : 16 - 24
  • [38] AMYOTROPHIC LATERAL SCLEROSIS - CURRENT CONCEPTS
    AMICO, LL
    ANTEL, JP
    POSTGRADUATE MEDICINE, 1981, 70 (02) : 50 - +
  • [39] THERAPEUTIC TRIALS IN AMYOTROPHIC-LATERAL-SCLEROSIS
    POTES, E
    CHERRY, S
    HOFFMAN, PM
    MAYER, RF
    MUSCLE & NERVE, 1986, 9 (05) : 106 - 106
  • [40] Amyotrophic lateral sclerosis:: From current developments in the laboratory to clinical implications
    Cozzolino, Mauro
    Ferri, Alberto
    Carri, Maria Teresa
    ANTIOXIDANTS & REDOX SIGNALING, 2008, 10 (03) : 405 - 443
12345